Jun 8, 2024, 03:28
Udhayvir Grewal: NICHE2 out now in NEJM
Udhayvir Grewal, Hematology and Oncology Fellow at the University of Iowa Holden Comprehensive Cancer Center, shared on X:
“NICHE2 out now in NEJM
- 116 patients with LA dMMR colon cancer
- Pathological response in 109 (98%; 95% CI, 94 to 100)
- major pathological response (defined as ≤10% residual viable tumor) in 105 (95%)
- pathological complete response (0% residual viable tumor) in 75 (68%)
- Grade 3 or more AEs 4%
- 26 months follow up- no recurrence More and more evidence emerging for Neoadjuvant IO (both in dMMR and now also pMMR/MSS disease).“
Source: Udhayvir Grewal/X